{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-066145","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.814058+00:00","generated_at":"2026-05-18T05:11:47.200334+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Aditxt subsidiary Pearsanta targets prostate cancer test launch by end-2025; IPO spin-off planned","bullets":["Pearsanta plans to launch a lab-developed test for prostate cancer using mitochondrial DNA detection by end of 2025.","CEO Amro Albanna stated 70% of cancer deaths could be prevented if caught early; Pearsanta aims for early detection via non-invasive blood test.","Aditxt plans to spin off Pearsanta via IPO, retaining ~60% ownership; values Aditxt's stake potentially at $60M vs. current $5M market cap.","The test will initially run at CLIA/CAP lab in Richmond, VA; FDA submission for kit development planned later.","Other subsidiaries highlighted: Adimune (autoimmunity) and pending Adifem/Evofem acquisition (women's health) expected to close by September 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-066145","json":"https://secwatch.observer/filing/0001213900-25-066145.json","markdown":"https://secwatch.observer/filing/0001213900-25-066145.md","text":"https://secwatch.observer/filing/0001213900-25-066145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025066145/0001213900-25-066145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025066145/ea0249677-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:11:47.200334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}